IL-6 Peptide Immunogen Constructs for Specific IL-6R Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current IL-6 vaccine designs face challenges such as complicated chemical coupling procedures, reliance on carrier proteins like KLH, use of disallowed adjuvants, weak immunogenicity, and unclear mechanisms, necessitating a need for an efficacious immunotherapeutic vaccine that generates specific immune responses against IL-6 dysregulation.
Innovation Solution
Development of IL-6 peptide immunogen constructs comprising B cell epitopes from IL-6R binding regions linked to heterologous T helper cell epitopes, formulated with adjuvants like CpG oligomers to stimulate highly specific antibodies targeting IL-6R binding sites, breaking immune tolerance and inhibiting IL-6 signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional IL-6 vaccine designs use carrier proteins like KLH and complicated chemical coupling procedures, then immunogenicity is enhanced, but manufacturing complexity increases and antibody specificity decreases
Solution Approach 1:
The patent segments the immunogen into defined peptide components: IL-6R binding region peptides (B cell epitopes) linked to T helper cell epitopes from pathogen proteins. This segmentation eliminates the need for complex carrier proteins like KLH while maintaining immunogenicity through controlled peptide assembly.
Solution Approach 2:
The patent uses defined peptide linkers as intermediaries to connect B cell epitopes to T helper epitopes, replacing complicated chemical coupling procedures with standardized peptide bonding. This intermediary approach simplifies manufacturing while ensuring proper spatial arrangement for immune recognition.
2Reliability
If conventional IL-6 vaccine designs use disallowed adjuvants, then immune response is enhanced, but safety compliance deteriorates
Solution Approach 1:
The patent changes the adjuvant parameter from disallowed substances to CpG oligomers, which are FDA-approved and safe. This parameter change maintains immune response enhancement through TLR9 activation while ensuring regulatory compliance and safety.
3Reliability
If conventional IL-6 vaccine designs rely on carrier proteins, then immunogenicity is improved, but antibody specificity against IL-6R binding sites decreases
Solution Approach 1:
The patent extracts only the essential immunogenic components: B cell epitopes from IL-6R binding regions and T helper epitopes from pathogen proteins. By removing unnecessary carrier proteins like KLH, the design ensures antibodies target only the intended IL-6R binding sites with high specificity.
4Ease of manufacture
If simple peptide constructs are used, then manufacturing is simplified, but immunogenicity and immune response strength weaken
Solution Approach 1:
The patent creates composite peptide constructs by combining B cell epitopes (from IL-6R binding regions) with T helper cell epitopes (from pathogen proteins) in defined ratios and configurations. This composite approach maintains manufacturing simplicity while achieving strong immunogenicity through synergistic immune cell activation.
Data Source
AI summary
The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-6 (IL-6) protein, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed IL-6 peptide immunogen constructs contain a B cell epitope from IL-6 linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The IL-6 peptide immunogen constructs stimulate the generation of highly specific antibodies directed to the IL-6 receptor (IL-6R) binding site for the prevention and/or treatment of diseases impacted by IL-6 dysregulation.